The LixiLan-L Trial: Consistent Findings in Glycemic Control, Body Weight, and Hypoglycemia With iGlarLixi Vs Insulin Glargine Across Baseline A1C, Body Mass Index, and Diabetes Duration

This exploratory analysis was conducted to determine the impact of patient baseline characteristics on outcomes observed in the LixiLan-L randomized open-label trial (N=736). This 30-week trial evaluated the efficacy and safety of iGlarLixi (insulin glargine 100 U [iGlar]) plus lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D). To be included in the study, patients were required to be inadequately controlled on a regimen of basal insulin alone or in combination with 1 or2 oral glucose-lowering drugs. Efficacy was assessed for the following patient subgroups: A1C <8 or ≥8%; T2D duration <10 or ≥10 years, and body mass index <30 or ≥30 kg/m2. Additionally, symptomatic hypoglycemia incidence (≤70 mg/dL) was analyzed. Investigators found that patients treated with iGlarLixi had consistently greater A1C reductions, were more likely to achieve an A1C target <7%, had reduced body weight gain, and experienced no differences in hypoglycemia incidence compared with patients receiving iGlar. The investigators concluded that iGlarLixi consistently improved blood glucose control in all patient subgroups, including difficult-to-treat patients with long diabetes duration, high A1C levels, and obesity. Click here for full article